home / stock / vera / vera news


VERA News and Press, Vera Therapeutics Inc.

Stock Information

Company Name: Vera Therapeutics Inc.
Stock Symbol: VERA
Market: NASDAQ
Website: veratx.com

Menu

VERA VERA Quote VERA Short VERA News VERA Articles VERA Message Board
Get VERA Alerts

News, Short Squeeze, Breakout and More Instantly...

VERA - Vera Therapeutics appoints David Johnson as COO

2024-07-01 08:15:40 ET More on Vera Therapeutics Vera Therapeutics: Waiting For A Pullback Vera gains FDA Breakthrough Therapy Designation for atacicept Read the full article on Seeking Alpha For further details see: Vera Therapeutics appoints David Johns...

VERA - Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L....

VERA - (VERA) Pivots Trading Plans and Risk Controls

2024-06-15 11:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

VERA - Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy ...

VERA - Vera gains FDA Breakthrough Therapy Designation for atacicept

2024-05-28 10:10:24 ET More on Vera Therapeutics Vera Therapeutics: Waiting For A Pullback Top 10 best performing biotech stocks of 2024 so far Seeking Alpha’s Quant Rating on Vera Therapeutics Historical earnings data for Vera Therapeutics Fin...

VERA - Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the U.S. Food and Drug ...

VERA - Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract; Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of participants than placebo; BRISBANE, Calif., May 25, 2024 (GLOBE NEWSW...

VERA - How To Trade (VERA)

2024-05-24 21:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

VERA - Vera Therapeutics GAAP EPS of -$0.56

2024-05-09 10:38:59 ET More on Vera Therapeutics Vera Therapeutics: Waiting For A Pullback Top 10 best performing biotech stocks of 2024 so far Seeking Alpha’s Quant Rating on Vera Therapeutics Historical earnings data for Vera Therapeutics Fin...

VERA - Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatment Topline 96-week data from ORIGIN 2 trial expected in Q4 2024 Pivotal Phase 3 ORIGIN 3 trial estimated to complet...

Next 10